Article Text

Download PDFPDF
Classification criteria: time for a rethink?

Statistics from Altmetric.com

Footnotes

  • Handling editor Josef S Smolen

  • Twitter @StefanSiebert1

  • Contributors All authors were involved in writing the article and in the decision to submit it for publication.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests NB: Research grants from Vifor, GSK, Pfizer, Novartis. Advisory board: Lilly, MSD. Speaking fees: Roche, Vifor, AbbVie. SS: GRAPPA global steering committee, ASAS member; research grants, speaker or consultancy fees from AbbVie, BMS, Boehringer-Ingelheim, Celgene, GSK, Janssen, Novartis, Pfizer and UCB.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.